| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Genenta Science S.p.A.$1.5
-0.09 (-5.66%)
F 10Pipeline Score Biotech · Pre-Clinical
Market Cap
13.59 M
EPS
-0.37
P/E Ratio
-
Value Trade
2.08 M
-15.32 %
Week
-16.2 %
1 Month
-33.64 %
3 Month
-66.86 %
6 Month
-94.23 %
5 Year
-94.23 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
41.64 K
52 Week Range
0.55 - 10
% held by Insiders
-
% held by Institutions
7.8 %
Enterprise Value
-10.54 M
Total Shares
23.43 M
Short %
-
Float Shares
-
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Genenta Science S.p.A.
23Total events
0Upcoming
6Tier-1 (high impact)
2022 – 2026Coverage
Event history 23
Apr 23, 2026
▲Partnership / LicenseCorporate
Genenta signs definitive agreements to acquire 51% stake in Sophia High Tech
Mar 25, 2026
◆FDA ApprovalFDA Decision
Shareholders' meeting scheduled to approve new corporate name Saentra Forge S.p.A. and new ticker SAEN
Mar 13, 2026
●Management ChangeCorporate
CEO Pierluigi Paracchi appointed to Board of Guarantors of Italian Academy at Columbia University
Mar 2026
◆PublicationTemferonPresentation
Nature Medicine accepts manuscript on GBM trial findings; publication expected in coming weeks
Glioblastoma Multiforme (GBM)source ↗
Jan 27, 2026
▲Partnership / LicenseTemferonCorporate
Engaged DC Advisory as exclusive financial advisor for partnership initiatives for Temferon and cell therapy platform
glioblastoma multiforme (GBM)source ↗
Jan 27, 2026
▼Program DiscontinuationCorporate
Company does not plan to internally advance the GU study and other clinical trials at this time
Dec 31, 2025
▲Quarterly UpdateCorporate
Preliminary cash, cash equivalents, and marketable securities at Dec 31, 2025 approximately $33 million
Nov 24, 2025
◆Full ResultsTemferonClinical Data
Long-term survival trends and immune findings from TEM-GBM study
newly diagnosed glioblastoma multiforme (GBM) with unmethylated MGMT (uMGMT) gene promotersource ↗
Oct 29, 2025
◆Quarterly UpdateCorporate
Ordinary and Extraordinary Shareholders' Meeting on October 29, 2025 (first call) or October 30, 2025 (second call)
Oct 28, 2025
Oct 26, 2025
Drug Pipeline Intelligence
F10
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 7%
Micro Cap (rank 849 of 912)
Percentile RankGenenta Science S.p.A. has significant pipeline risk (10/100).
Showing 0 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Temferon | newly diagnosed glioblastoma multiforme | Phase 1 | 2025-11-24 | 25 patients have been treated with Temferon | Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial Read More | |
Temferon | newly diagnosed glioblastoma multiforme | Phase 1 | 2025-11-24 | 25 patients have been treated with Temferon | Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial Read More | |
Temferon | newly diagnosed glioblastoma multiforme | Phase 1 | 2025-11-24 | 25 patients have been treated with Temferon | Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GNTA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GNTA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GNTAGenenta signs Definitive Agreements with Sophia High Tech Genenta enters aerospace as it continues its strategic transformation into a next-generation industrial consolidator Milan, Italy
Genenta Science S.p.A. (Nasdaq: GNTA) has entered into definitive agreements with Sophia High Tech S.r.l. to acquire a controlling stake as part of its strategic transformation into Saentra Forge. This move aims to consolidate operations across multiple sectors, including aerospace and national security technologies. With an initial 19.9% stake and plans to increase to 51%, Genenta expects to enhance production capacity and profitability at Sophia HT, which reported solid financial performance in its recent fiscal year. The partnership will also involve overcoming regulatory hurdles and obtaining shareholder approval.
Read more →GNTA▼ -14.3%on this news
Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs
Genenta Science S.p.A., transitioning to Saentra Forge, has signed a binding offer with Sòphia High Tech, an Italian aerospace and defense manufacturer. The deal involves funding Sòphia through two capital increases, aiming for a controlling stake based on performance milestones. This strategic acquisition is expected to bolster Genenta's capabilities in critical sectors, including biotechnology and national security.
Read more →GNTAGenenta Science S.p.A. Registered office: Milan, via Dell'Annunciata 31 Subscribed and paid-up share capital of Euro 893,218.30 Tax code and registration number with the Milan Monza-Brianza Lodi Companies' Register: 0873
Genenta Science S.p.A. has announced the revocation of its previously scheduled Extraordinary Shareholders' Meeting, which aimed to discuss a proposed name change to Saentra Forge S.p.A. The Board's decision stems from the brand recognition and market presence that 'Genenta' has built over the past decade. Additionally, the company's ongoing development of its corporate purpose remains in the early stages. The Board continues to view the strategic adoption of a new name as an important goal moving forward.
Read more →GNTA▲ +8.2%on this newsshared move
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
Genenta Science S.p.A., transitioning to Saentra Forge, is exploring collaboration opportunities for its biotechnology platform. Despite not having active discussions with potential partners, the company remains committed to leveraging its scientific foundation. CEO Pierluigi Paracchi emphasizes the importance of retaining technological value in Italy while focusing on long-term shareholder interests.
Read more →GNTAGenenta, Evolving into Saentra Forge, Announces CEO’s Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University
Genenta Science S.p.A., soon to be renamed Saentra Forge, announced the appointment of CEO Pierluigi Paracchi to the Board of Guarantors of the Italian Academy at Columbia University. This prestigious role aims to strengthen intellectual and cultural ties between Italy and the U.S. Paracchi emphasized the importance of connecting science, industry, and international collaboration.
Read more →GNTAGenenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform
Genenta Science S.p.A. is transitioning to Saentra Forge, focusing on biotech and defense technologies. The company appointed Paolo Salvato to its Board of Directors to enhance governance in defense manufacturing. Additionally, Genenta is evaluating acquisition opportunities in national-security sectors and has a manuscript accepted for publication regarding its Glioblastoma Multiforme trial, indicating progress in its biotech initiatives.
Read more →GNTA▲ +18.5%on this news
Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator
Genenta Science S.p.A. is undergoing a strategic transformation to become Saentra Forge S.p.A., focusing on acquiring businesses in national security sectors. The company has initiated its first integration with ATC, a defense manufacturer, and plans to enhance its operations. Additionally, Genenta aims to leverage partnerships for its cell therapy platform while maintaining a strong financial position.
Read more →GNTA▲ +6%on this news· ran to +20% by day 3
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
Genenta Science has reported consistent long-term survival metrics from its TEM-GBM study involving newly diagnosed glioblastoma multiforme patients. The study also reveals early immune responses to Temferon, indicating its potential effectiveness in the tumor microenvironment. However, these findings are preliminary and require further validation in larger trials. Genenta continues to maintain a strong financial position to support its ongoing research.
Read more →GNTA▼ -46.5%on this news· ran to -61% by day 1
Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares Milan, Italy and New York, USA
Genenta Science announced a registered direct offering of 4,285,715 American Depositary Shares at $3.50 per share, raising approximately $15 million. The funds will be allocated for working capital and corporate purposes, supporting ongoing clinical trials, including for their proprietary therapy, Temferon. The offering is set to close by October 28, 2025, pending customary closing conditions. However, the company notes potential risks associated with these forward-looking statements and the investigational status of their therapies.
Read more →GNTAGenenta Science S.p.A. Consolidated Statements of Operations and Comprehensive Loss 2025 2024 Six Months Ended
Genenta Science S.p.A. released its consolidated statements of operations and comprehensive loss for the six months ending in 2025 and 2024. The document primarily details various accounting measures related to common stock, retained earnings, and comprehensive income. However, the text does not provide specific financial performance metrics or forward-looking statements that might indicate the company's operational health or strategic direction.
Read more →GNTAGenenta Science S.p.A. Registered office: Milano, via Olgettina n. 58 Share capital subscribed and paid equal to Euro 464.646,80 tax code and entry number on Milan Monza - Brianza Lodi Companies Register: 08738490963 NOT
Genenta Science S.p.A. has announced a notice for its ordinary and extraordinary shareholders' meeting scheduled for October 29, 2025. The meeting will be conducted exclusively via teleconference to discuss key agenda items, including the increase in the Board of Directors' membership. Shareholders eligible to vote must notify the company of their intention to attend and provide requisite documentation by October 24, 2025. This meeting aims to facilitate shareholder engagement and address governance enhancements.
Read more →GNTAGenenta Announces 20 million ($20.9M) Financing to Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates Milan, Italy and New York, USA
Genenta Science (Nasdaq: GNTA) has announced a financing deal worth $20 million to advance its pipeline, particularly its Temferon treatment for metastatic Renal Cell Cancer (mRCC). The funding, sourced through a Mandatory Convertible Bond from ENEA Tech and Biomedical (ETB), is set up to avoid immediate dilution of current shareholder equity. Meanwhile, recent data from the Phase 1/2a trial for Glioblastoma Multiforme shows improved survival rates, now at 29%, which reflects positively on the company's ongoing research. The bond investment is seen as a critical step towards supporting Genenta's clinical trials while also reinforcing its financial position.
Read more →GNTAGenenta Science S.p.A. Consolidated Statements of Operations and Comprehensive Loss 2024 2023 Six Months Ended
Genenta Science S.p.A. has released their consolidated statements of operations and comprehensive loss for the six months ended in 2024 and 2023. The article mainly lists financial terms and classifications without providing specific details regarding financial performance or results. This lack of detailed information could imply difficulties in reporting or overall business conditions.
Read more →GNTA▼ -7.5%on this news
Genenta Science S.p.A. Registered office: Milano, via Olgettina n. 58 Share capital subscribed and paid equal to Euro 371.685,80 tax code and entry number on Milan Monza - Brianza Lodi Companies Register: 08738490963 NOT
Genenta Science S.p.A. has announced a shareholders' meeting scheduled for April 29, 2024. The meeting aims to address key issues such as the approval of financial statements for 2023, the appointment of the Board of Directors and Statutory Auditors, and potential amendments to the bylaws. Participation will be remote, requiring shareholders to register in advance and provide necessary documentation. The final date for slates to be submitted is April 4, 2024.
Read more →GNTAGenenta Science S.p.A. Consolidated Statements of Operations and Comprehensive Loss 2023 2022 Six Months Ended
Genenta Science S.p.A. has published its consolidated statements for the operations and comprehensive loss for the six months ending in 2023 and 2022. The document raises concerns due to its complex presentation and lack of clear financial insights. Many entries pertain to related parties, which may complicate the evaluation of true financial health.
Read more →GNTAGenenta Science S.p.A. (formerly, Genenta Science S.r.l.) Consolidated Statements of Operations and Comprehensive Loss 2022 2021 Six Months Ended
GENENTA SCIENCE S.P.A. GNTA:CorporateCapitalMember us-gaap:AdditionalPaidInCapitalMember us-gaap:CommonStockMember us-gaap:RetainedEarningsMember GNTA:CorporateCapitalMember us-gaap:AdditionalPaidInCapitalMember us-gaap:CommonStockMember us-gaap:RetainedEarningsMember GN
Read more →GNTAGenenta Provides First Half 2022 Business Update and Financial Results
Provides First Half 2022 Business Update and Financial Results Current dose escalation study data shows a median overall survival of 17 months Adding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimen Cash and cash equivalents of 34.7 million as of Jun
Read more →GNTAGenenta Science S.p.A. Registered office: Milan, via Olgettina n. 58 Subscribed and paid-up share capital of 371,685.80 Tax code and registration number with the Milan Monza - Brianza Lodi Register of Companies: 08738490
office: Milan, via Olgettina n. 58 and paid-up share capital of 371,685.80 code and registration number with the Milan Monza - Brianza Lodi Register of Companies: 08738490963 OF CALL OF ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING shareholders of Genenta Science S.p.A. (t
Read more →Competitive Position
How GNTA ranks across every disease it competes inCompetitive Position is a premium feature
See how GNTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial